- Please check and comment entries here.
Integrins belong to a group of cell adhesion molecules (CAMs) which is a large group of membrane-bound proteins. They are involved both in cell attachment to the extracellular matrix (ECM) and in signal transduction from the ECM to the cells. They also take part in numerous biological activities, namely extravasation, cell-to-cell adhesion, cell migration, and function as receptors for certain viruses, including adenovirus, echovirus, hantavirus, foot-and-mouth disease, polio virus and severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2). CAMs also include selectins, cadherins, immunoglobulin superfamily and other molecules, including CD44. Cell adhesion molecules are classified using the CD nomenclature (from 1 to 130). Integrins receive and transmit biochemical and mechanical signals through the cell membrane in both directions. Signals which develop inside the cell lead to conformational changes of the molecule and transmission of integrin into a state which enables ligand binding. The name “integrins” has been coined to denote the function they have maintaining a multicellular organism as a whole. They significantly affect the integrity of the cytoskeleton–ECM connections.
1. Integrin Structure
Integrins are heterodimeric glycoproteins which serve a function of transmembrane receptors. They are composed of two chains, α and β, which can be joined together making 24 combinations of various heterodimers. These chains are noncovalently associated. The spatial structure of integrins resembles the human body . The “head” is based on two “legs” which are changed into the transmembrane domain. Interactions between the α and β subunits usually take place in the “head.” The α chain is composed of a seven-bladed β-propeller joined with a thigh, calf-1 and calf-2 domains. This structure supports the integrin head. The last three or four blades of the β-propeller include domains that bind Ca2+. The β chain is composed of βI, hybrid and PSI (plexin/semaphorin/integrin) domains and four cysteine-rich epidermal growth factor-like (EGF) modules. The βI domain contains Mg2+. Divalent ions are essential for normal function of integrins. Each ion has a different function. Mn2+ and Mg2+ activate adhesion processes. Ca2+ ions, depending on concentration, may have an inhibitory or stimulatory effect. High Ca2+ concentration inhibits adhesion, whereas low Ca2+ concentration with optimal Mg2+ concentration stimulates binding of a ligand with an integrin .
2. Integrin Activation
Knowing the mechanism of integrin activation enables searching for new therapies of many diseases, e.g., cardiovascular diseases (venous emboli, myocardial infarctions), inflammatory diseases, allergies and metastatic processes. The presence and activity of integrins depend on numerous factors, which can be activators or inhibitors. These include hormones, cytokines, mediators of systemic inflammation, active components of the complement system, active oxygen species, endotoxins or pharmacological compounds. A change in the expression of integrin receptors usually takes place at the transcription level. Integrin activation leads to molecular transformation, which enables ligand binding .
Intracellular domains of both chains bind directly or indirectly with the cellular actin-based cytoskeleton . Depending on the signal direction, integrin activation may take place in two ways: as outside–in signaling or inside–out signaling. In the case of outside–in signal transduction, ligand binding to extracellular domains of an integrin causes a shift of the subunit “head” segments, elongation of the integrin in the “knee” region and extending the whole structure. As a result, the domains forming the “legs” move apart. The transmembrane and cytoplasmic regions of both subunits are moved apart, too. This way, the integrin molecule is activated, showing a higher affinity to ligands. Then, clustering occurs, which in turn initiates adhesion processes between the cell and the extracellular matrix. In the case of inside–out activation, ligand conjugation is not necessary to activate an integrin. Such activation is mediated by intracellular proteins bound to the cytoplasmic skeleton: kindlin, talin and migflin .
Integrins occur in three various spatial configurations: closed, activated (extended-closed) and active (extended-open) conformations. During transition from a closed to activated conformation, there occurs extension of the integrin between calf-1 and thigh in the α subunit and between I–EGF-1 and I–EGF-2 in the β subunit .
The integrin molecule is rich in cysteine residues which form disulfide bridges. A transition of an integrin from its inactive form to a form enabling ligand binding is preceded by reorganization of disulfide bonds inside the molecule. This reaction is catalyzed by protein disulfide isomerase (PDI). An example of PDI participation in integrin activation is the process of platelet aggregation. The PDI count is much lower in inactive platelets than during activation. Using anti-PDI antibodies, inhibition of blood platelet aggregation was observed. Other examples involve processes taking place in vascular endothelial cells. Mn2+ ions initiate formation of relatively stable complexes between the αVβ3 integrin and PDI .
3. Integrin Classification
Vertebrates have 18 α and eight β subunits, which form various heterodimers. Integrin heterodimers contain a number of combinations of α and β subunits. Depending on the type of the ligand bound, integrins can be classified as collagen-binding integrins (α1β1, α2β1, α10β1, α11β1), integrins recognizing the RGD motif (the triple amino acid sequence arginine–glycine–aspartic acid (α5β1, αVβ1, αVβ3, αVβ5, αVβ6, αVβ8, αIIbβ3, α8β1)), laminin-binding integrins (α3β1, α6β1, α7β1, α6β4) and leukocyte-binding integrins (αLβ2, αMβ2, αXβ2, αDβ2). The β2 integrin subunit (CD18) is able to couple to one of the α subunits (αL-CD11a, αM-CD11b, αX-CD11c, αD-CD11d) to form lymphocyte function-associated antigen-1 (LFA-1/αLβ2/CD11a/CD18), macrophage-1 antigen/complement receptor 3 (Mac1/CR3/αMβ2/CD11b/CD18) and complement receptor 4 (p150,95/CR4/CD11c/CD18). The CD11a/CD18 is present mainly on all leukocytes, whereas CD11b/CD18, CD11c/CD18 and CD11d/CD18 are found on myeloid cells. The αMβ2 integrin (also known as CR3, CD11b/CD18 or Mac-1) is expressed on phagocytic cells and engaged in the adhesion of leukocytes to the endothelium and microbial opsonization. Ligands for CR3 contain the complement component iC3b, the intercellular adhesion molecule (ICAM-1) and coagulation factors such as fibrinogen and factor X .
Another classification is based on the presence of the αI domain. Belonging to one of the integrin families depends on the β chain (with the most important β1, β2 and β7 chains) combined with various α chains. Each of the β subunits may form a heterodimeric receptor with various α subunits. An exception is the αV subunit, which binds several different β subunits, e.g., αVβ1, αVβ3, αVβ5, αVβ6. Since they may appear at 2–7 weeks after lymphocyte stimulation, β1 integrins are called very late antigens (VLA) or CD29. They participate in the binding of cells with the extracellular matrix. They bind laminin, fibronectin, vitronectin, collagen and other proteins of the extracellular matrix; therefore, they serve an important function in cell adhesion to the background. They occur on numerous cells of the immune system. They are absent on erythrocytes. Eosinophils show a presence of the α4β1 and α6β1 integrins, α4β1 and α5β1 basophils, α3β1, α4β1 and α5β1 mastocytes. Neutrophils contain all the β1 integrins, except for the α4β1 integrin. On the other hand, β2 integrins are present on cell membranes of all leukocyte populations. This subunit can be linked with one of the three α subunits which form the CD11a, CD11b, CD11c titer. The group of β2 integrins contains the LFA-1, Mac-1 and GP-150/95 glycoproteins. The CD11a/CD18 integrin is called LFA-1 (leukocyte function-associated antigen) since these antigens are found only on leukocytes. The Mac-1 integrins occur in their inactive form on neutrophils, monocytes and NK cells. Activation and binding with ICAM-1 is caused by inflammatory factors. As a result, neutrophils are bound to endothelial cells .
Integrin ligands also include receptors, which belong to a family of immunoglobulin-like CAMs such as ICAM-1, vascular cell adhesion molecule 1 (VCAM 1). They occur, e.g., on the surface of endothelial cells. These connections are characterized by high bond strength. ICAM-1 is a ligand for the CD11a/CD18 integrin. ICAM-1 synthesis is triggered by TNF-α, IL-1 and interferon gamma (IFNγ), endotoxin. ICAM-2 binds to the CD11b/CD18 integrin. The CD11a/CD18 and CD11b/CD18 integrins play the most important role in the inflammatory process . Integrins are also able to bind very different proteins of the extracellular matrix, e.g., fibronectin, fibrinogen, vitronectin, laminin, collagen, plasminogen, osteopontin, von Willebrand factor or sialoprotein of the matrix skeleton . The alternative name for β3 integrins is cytoadhesins. They play a major role in the adhesion and aggregation of blood platelets and in the formation of complexes. Recognizing the RGD sequence, they bind fibrinogen, vitronectin, fibronectin and von Willebrand factor. They include platelet adhesion gpIIb/IIIa (CD61/CD41) and receptor for vitronectin (CD61/CD51) which occurs on the endothelium and the macrophage cell membrane .
Integrin ligands may also include proteolysis-triggered endostatin (coming from type XVIII collagen), endorepellin and tumstatin. Moreover, integrins may also bind viper venom toxins called disintegrins, certain viruses and bacteria . Various pathogens, e.g., echoviruses, adenoviruses, and herpesviruses use integrins to penetrate cells. Integrins may be receptors for SARS-CoV-2 and can be implicated in transmission and pathology of SARS-CoV-2 .
4. Integrin Function
Integrins play an important role in physiological and pathological processes, as well as in wound-healing processes. The specificity of the inflammatory process depends on adequate expression of adhesion molecules enabling leukocyte migration.
During inflammation, integrins enable white blood cells to cross the vascular wall. On the leukocyte membrane, β2 integrins bind ICAM-1 whereas α4β1 and α4β7 bind VCAM-1 on endothelial cells . The integrin α4 subunit can dimerize with either the β1 or β7 subunit to form the α4β1 or α4β7 integrin. During inflammation, α4β1 promotes transendothelial lymphocyte migration into the inflamed tissue, whereas α4β7 helps in lymphocyte migration into the intestinal mucosal lymphoid tissues . In addition, the α4β1 integrin can interact with vascular endothelial growth factor/VEGF receptor 2 (VEGF/VEGFR2) and/or contributes to VEGF functions in chronic lymphocytic leukemia (CLL) .
The adhesion and binding of leukocytes to the surface of the vascular endothelium result from the connection of the β2 integrin of the leukocyte membrane with endothelial cells. A similar mechanism of adhesion to the vascular endothelium applies to circulating neoplastic cells. These interactions are essential for crossing the vascular barrier and forming metastasis. It has been demonstrated that the occurrence of β4 and α6 integrins on the cells of squamous cell carcinoma is increased. The CD11b/CD18 integrin (β2) mediates responses to Gram-negative bacteria while interleukin 1 takes part in the migration of inflammatory cells. In the case of infection with Gram-positive bacteria, cells migrate via a CD11b/CD18-independent pathway .
Mutations in integrin subunits may cause various genetic diseases in humans. Three autosomal recessive diseases have been described: Glanzmann’s thrombasthenia (mutations of the αIIb and β3 integrins), leukocyte adhesion deficiency (LAD)—caused by point mutations or deletion of a gene in the β2 integrin—characterized by hereditary deficiency syndrome  and vesicular epidermal necrolysis caused by mutation of the α6β4 integrin .
The entry is from 10.3390/cells10071703
- Mezu-Ndubuisi, O.J.; Maheshwari, A. The role of integrins in inflammation and angiogenesis. Pediatr. Res. 2020.
- Campbell, I.D.; Humphries, M.J. Integrin structure, activation, and interactions. Cold Spring Harb. Perspect. Biol. 2011, 3, a004994.
- Sigrist, C.J.; Bridge, A.; Le Mercier, P. A potential role for integrins in host cell entry by SARS-CoV-2. Antiviral. Res. 2020, 177, 104759.
- Bednarczyk, M.; Stege, H.; Grabbe, S.; Bros, M. β2 Integrins-Multi-Functional Leukocyte Receptors in Health and Disease. Int. J. Mol. Sci. 2020, 21, 1402.
- Mould, A.P.; Akiyam, S.K.; Humphries, M.J. Regulationof integrin α5β1-fobronectin interactions by divalent cations.Evidence for distinct chesses of binding sites for Mn2+,Mg2+ and Ca2+. J. Biol. Chem. 1995, 270, 26270–26277.
- Nair, K.S.; Naidoo, R.; Chetty, R. Expression of cell adhesion molecules in oesophageal carcinoma and its prognostic value. J. Clin. Pathol. 2005, 58, 343–351.
- Shi, M.; Foo, S.Y.; Tan, S.M. A structural hypothesis for the transition between bent and extended conformations of the leukocyte beta2 integrins. J. Biol. Chem. 2007, 282, 30198–30206.
- Swiatkowska, M.; Szymański, J.; Padula, G. Interaction and functional association of protein disulfide isomerase with alphaVbeta3 integrin on endothelial cells. FEBS J. 2008, 275, 1813–1823.
- Fagerholm, S.C.; Guenther, C.; Asens, M.L.; Savinko, T.; Uotila, L.M. Beta2-integrins and interacting proteins in leukocyte trafficking, immune suppression, and immunodeficiency disease. Front. Immunol. 2019, 10, 254.
- Bunting, M.; Harris, E.S.; McIntyre, T.M.; Prescott, S.M.; Zimmerman, G.A. Leukocyte adhesion deficiency syndromes: Adhesion and tethering defects involving beta 2 integrins and selectin ligands. Curr. Opin. Hematol. 2002, 9, 30–35.
- Yonekawa, K.; Harlan, J.M. Targeting leukocyte integrins in human diseases. J. Leukoc. Biol. 2005, 77, 129–140.
- Stewart, P.; Nemerov, G. Cell integrins:commonly used receptors for diverse viral pathogens. Trends Microbiol. 2007, 15, 500–507.
- Larsen, M.; Artym, V.; Green, J.A. The matrix reorganized: Extracellular matrix remogeling and integrin signaling. Curr. Opin. Cell Biol. 2006, 185, 463–471.
- Kourtzelis, I.; Mitroulis, I.; von Renesse, J. From leukocyte recruitment to resolution of inflammation: The cardinal role of integrins. J. Leukoc. Biol. 2017, 102, 677–683.
- Salazar-Noratto, G.E.; De Nijs, N.; Stevens, H.Y. Regional gene expression analysis of multiple tissues in an experimental animal model of post-traumatic osteoarthritis. Osteoarthr. Cartil. 2019, 27, 294–303.
- Miyamoto, S.; Katz, B.; Lafrenie, R. Fibronectin and integrins in cell adhesion, signaling and morphogenesis. Ann. N. Y. Acad. Sci. 1998, 857, 119–129.
- Tsai, W.B.; Grunkemeier, J.M.; McFarland, C.D. Platelet adhesion to polystyrene-based surfaces preadsorbed with plasmas selectively depleted in fibrinogen, fibronectin, vitronectin, or von Willebrand’s factor. J. Biomed. Mater. Res. 2002, 60, 348–359.
- Hauck, C.R.; Agerer, F.; Muenzner, P. Cellular adhesion molecules as targets for bacterial infection. Eur. J. Cell Biol. 2006, 85, 235–242.
- Gorina, R.; Lyck, R.; Vestweber, D.; Engelhardt, B. β2 integrin-mediated crawling on endothelial ICAM-1 and ICAM-2 is a prerequisite for transcellular neutrophil diapedesis across the inflamed blood-brain barrier. J. Immunol. 2014, 192, 324–337.
- Chang, A.C.; Chen, P.C.; Lin, Y.F.; Su, C.M.; Liu, J.F.; Lin, T.H.; Chuang, S.M.; Tang, C.H. Osteoblast-secreted WISP-1 promotes adherence of prostate cancer cells to bone via the VCAM-1/integrin α4β1 system. Cancer Lett. 2018, 426, 47–56.
- Sackstein, R. The lymphocyte homing receptors: Gatekeepers of the multistep paradigm. Curr. Opin. Hematol. 2005, 12, 444–450.
- Gutiérrez-González, A.; Aguilera-Montilla, N.; Ugarte-Berzal, E. α4β1 integrin associates with VEGFR2 in (CLL) cells and contributes to VEGF binding and intracellular signaling. Blood Adv. 2019, 3, 2144–2148.
- Ruoslahti, E. Integrins as signaling molecules and targets for tumor therapy. Kidney Int. 1997, 51, 1413–1417.
- Patriarca, C.; Alfano, R.M.; Sonnenberg, A. Integrin laminin receptor profile of pulmonary squamous cell adenocarcinomas. Hum. Pathol. 1998, 29, 1208–1215.
- Savoiu, P.; Trusoino, L.; Pepino, E. Expression and topography of integrins and basement membrane proteins in epidermal carcinomas. J. Investig. Dermatol. 1993, 101, 352–358.
- Hogg, N.; Bates, P.A. Genetic analysis of integrin function in man:LAD-1 and other Syndromes. Matrix Biol. 2000, 19, 211–222.
- Pulkkinen, L.; Kim, D.; Uitto, J. Epidermolysis bullosa with pyloric artresia: Novel mutations in the β4 integrin gene (ITGB4). Am. J. Pathol. 1998, 152, 157–166.
- Ruzzi, L.; Gagnoux-Palacios, L.; Pinola, M. A homozygous mutation in the integrin α6 gene in junctional epidermolysis bullosa with pyrolic atresia. J. Clin. Investig. 1997, 99, 2826–2831.